Comparison of Efficacy,Safety and Economy Between Generic and Original-Patented Cefuroxime Sodium for Injection in the Treatment of Pediatric Bronchopneumonia
Objective To compare the efficacy,safety and economy of generic and original-patented Cefuroxime Sodium for Injection in the treatment of pediatric bronchopneumonia.Methods Basic information and clinical data of children with bronchopneumonia treated with Cefuroxime Sodium for Injection at the Second People's Hospital of Hefei from January 2019 to December 2022 were extracted from the hospital information system archive database.The above children were divided into the generic group and the original-patented group according to different drugs.The efficacy was evaluated based on clinical effective rate and cases of bacterial clearance.The safety was evaluated based on the incidence of adverse reactions.The cefuroxime sodium fees was taken as the drug costs to calculate the costs and cost-effectiveness ratio.Results After matching at a ratio of 1∶2 by the propensity score matching,104 cases and 208 cases were included in the generic group and the original-patented group respectively.There was no significant difference in the clinical effective rate,cases of bacterial clearance and incidence of adverse reactions between the two groups(P>0.05).The cost-effectiveness ratio in the generic group was 2.26,which was significantly lower than 11.41 in the original-patented group.Conclusion The efficacy and safety of generic and original-patented Cefuroxime Sodium for Injection is consistent in clinical practice,while generic drugs are more economical.
real world studyCefuroxime Sodium for Injectiongeneric drugoriginal-patented drugclinical efficacysafetyeconomy
国家科技期刊平台
NSTL
万方数据
